1. Problematic social media use and relationship to mental health characteristics in youth from the Texas Youth Depression and Suicide Research Network (TX-YDSRN).
- Author
-
Kennard BD, Hughes JL, Minhajuddin A, Jones SM, Jha MK, Slater H, Mayes TL, Storch EA, LaGrone JM, Martin SL, Hamilton JL, Wildman R, Pitts S, Blader JC, Upshaw BM, Garcia EK, Wakefield SM, and Trivedi MH
- Abstract
Background: The relationship between social media and mental health, particularly in youth, is an area of concern for researchers, clinicians, and parents. Rising rates of screen time have coincided with an increase in youth mental health issues, emphasizing the need to investigate the prevalence and clinical correlates of problematic social media use., Methods: Our sample is a 489-participant sub-sample of the Texas Youth Depression and Suicide Research Network (TX-YDSRN) Registry, which is comprised of Texas youth receiving care for depression, suicidal ideation and/or suicidal behaviors. Prevalence of problematic social media use was identified, and indicators of mental and physical health were compared in those with or without problematic use., Results: In our sample, 40.3 % of participants reported problematic social media use, and those with problematic use were more likely to report higher amounts of screen time. Relative to non-problematic users, problematic users endorsed more and higher depressive symptoms, anxiety, and suicidal thoughts, as well as poorer wellness factors. Participants with high duration and problematic use had poorer outcomes than those with low duration and non-problematic use., Limitations: The cross-sectional design does not allow for control comparisons and is limited by use of a single time point. Data are mainly derived from self-report measures, and generalizability of the findings may be impacted by overrepresentation of white females in the sample., Conclusions: As use increases, these data contribute to the empirical literature on the complex relationship between social media and mental wellbeing, suggesting problematic use is associated with poor mental health outcomes., Competing Interests: Declaration of competing interest Betsy D. Kennard has research support from the American Foundation for Suicide Prevention, the National Institutes of Health, the Patient-Centered Outcomes Research Institute, and the State of Texas. Dr. Kennard receives royalties from Guilford Press and is on the board of the Jerry M. Lewis MD Research Foundation and the George G. and Alva Hudson Smith Foundation. Jennifer L. Hughes receives royalties from Guilford Press and is on the board of the American Psychological Association (APA) Division 53, Society for Clinical Child and Adolescent Psychology (SCCAP). Dr. Hughes has served as Youth Aware of Mental Health (YAM) trainer with Mental Health in Mind International and consulted for the Jed Foundation, community mental health organizations, and state projects on quality improvement interventions for depression and suicidal/self-harm behavior. Dr. Hughes has research support from the American Foundation for Suicide Prevention (AFSP) and the National Institutes of Health (NIH). Eric A. Storch reports receiving research funding to his institution from the Ream Foundation, International OCD Foundation, and NIH. He was formerly a consultant for Brainsway and Biohaven Pharmaceuticals in the past 12 months. He owns stock less than $5000 in NView/Proem for distribution related to the YBOCS scales. He receives book royalties from Elsevier, Wiley, Oxford, American Psychological Association, Guildford, Springer, Routledge, and Jessica Kingsley. In the past 12 months, Manish K. Jha has received contract research grants from Neurocrine Bioscience, Navitor/Supernus and Janssen Research & Development; honorarium to serve as Section Editor of the Psychiatry & Behavioral Health Learning Network and as Guest Editor for Psychiatric Clinics of North America from Elsevier; consultant fees from Eleusis Therapeutics US, Inc, Janssen Scientific Affairs, and Boehringer Ingelheim; fees to serve on Data Safety and Monitoring Board for Worldwide Clinical Trials (Eliem and Inversargo), Vicore Pharma and IQVIA (Click); and honoraria for educational presentations from North American Center for Continuing Medical Education, Medscape/WebMD, Clinical Care Options, and H.C. Wainwright & Co. Joseph C. Blader reports serving as a paid consultant and speaker for Supernus Pharmaceuticals. Sarah M. Wakefield serves as an Executive Committee Member of the Texas Child Mental Health Care Consortium. Madhukar H. Trivedi has provided consulting services to Acadia Pharmaceuticals, Alkermes Inc., Alto Neuroscience Inc, Axsome Therapeutics, BasePoint Health management LLC, Biogen MA Inc, Cerebral Inc., Circular Genomics Inc., Compass Pathfinder Limited, Daiichi Sankyo Inc., GH Research, GreenLight VitalSign6 Inc, Heading Health, Janssen Pharmaceutical, Legion Health, Merck Sharp & Dohme Corp., Mind Medicine Inc., Myriad Neuroscience, Naki Health Ltd, Neurocrine Biosciences Inc., Noema Pharma AG, Orexo US Inc., Otsuka America Pharmaceutical Inc., Otsuka Europe LTD, Otsuka Pharmaceutical Development & Commercialization Inc., Praxis Precision Medicines Inc, PureTech LYT Inc, Relmada Therapeutics Inc., SAGE Therapeutics, Signant Health, Sparian Biosciences, Titan Pharmaceuticals, Takeda Pharmaceuticals Inc, WebMD. He has received grant/research funding from NIMH, NIDA, NCATS, American Foundation for Suicide Prevention, Patient-Centered Outcomes Research Institute (PCORI), Blue Cross Blue Shield of Texas, SAMHSA, and the DoD. Additionally, he has received editorial compensation from Elsevier and Oxford University Press. Abu Minhajuddin, Sophia M. Jones, Holli Slater, Taryn L. Mayes, Jacquelyn M. Lagrone, Sarah L. Martin, Jessica L. Hamilton, Rebecca Wildman, Shamari Pitts, Blake M. Upshaw, and E’Lenya K. Garcia declare no competing interests., (Copyright © 2025 Elsevier B.V. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF